CRSP CRISPR Therapeutics AG Insider Trading

CEO Kulkarni Samarth sold 9,798 shares of CRSP at $52.80 on 2026-03-11, stock now down -36.4% from 52-week high at $48.87.

Kulkarni Samarth, CEO, sold 9,798 shares at $52.80, reducing his position by 4.0% to 235.6K shares. The sale occurred at a price 8.1% above the current market price of $48.87, and notably the stock has declined -36.4% from its 52-week high of $76.78. CRSP's fundamentals are deteriorating: the company reported -90.6% annual revenue decline with quarterly revenue of $889.0K and a net loss of $106.4M. Across his cross-ticker track record, the insider has executed 20 prior sales with a 100.00% well-timed rate at the 90-day mark (averaging -17.5% 90-day returns after sells). At CRSP specifically, his prior two measurable sales both exhibited negative 90-day returns (-22.6% and -9.7%), indicating a consistent pattern of selling before subsequent declines in this security.

CMO Patel Naimish buys inaugural 1,508 shares of CRSP at $32.96 amid company's -90.0% annual revenue decline and $-106.4M net loss.

Patel Naimish, Chief Medical Officer, purchased 1,508 shares at $32.96 on 2025-04-03, establishing an initial position in CRSP. This is notable given the company's severe financial deterioration: annual revenue growth stands at -90.0% with a latest-quarter revenue of $889.0K, and the company posted a full-year net income of $-106.4M. The buy occurs when the stock trades 29.3% below its 52-week high of $76.78, and the 90-day decline of -13.3% suggests recent downward momentum. As a first-time buyer with no prior holdings, this represents a new commitment to company stock at a significantly depressed valuation relative to recent price history, though the company's profitability crisis remains unresolved.

CRSP CFO sells 34,972 shares at $60.19 for $2.1M; holds just 6,767 post-trade amid -90.0% revenue decline and -$106.4M net loss

Prasad Raju sold 34,972 shares (83.8% of pre-transaction holdings) at $60.19 on 2026-01-22, exiting nearly the entire position and retaining only 6,767 shares worth $368,757 at the $54.65 current price. The CFO's action occurs against a backdrop of severe operational deterioration: annual revenue collapsed 90.0% to $889.0K quarterly run-rate, the company reported a $-106.4M net loss in its most recent fiscal year, and the stock has declined 28.8% from its 52-week high of $76.78. His cross-ticker track record shows 6 prior sells averaging -2.4% returns over 30 days, and at CRSP specifically he has conducted five prior sales since 2025-12-22, three executed just 16 days before this transaction. The dramatic concentration of sales in a three-week window (2025-12-22 and 2026-01-06 dates, plus this 2026-01-22 sale) combined with the near-total liquidation of his position suggests structured reductions rather than opportunistic selling, yet the company's financial deterioration provides clear contextual weight to the timing.

CEO Kulkarni sells 90,000 CRSP shares across 3 trades (Jan 20–22) for $5.2M at blended avg $57.40; holdings drop 40.1% to 134.2K shares.

Kulkarni executed 3 separate sales totaling 90,000 shares for $5,166,297.83, reducing his stake by 40.1% from 224.2K to 134.2K shares. The multi-day execution (Jan 20–22) across three distinct price points ($51.61, $52.10, $60.23) occurred in the context of the stock trading near its 52-week high at the time of the highest-priced tranche ($60.23 on Jan 22). At CRSP specifically, Kulkarni's prior 5 trades all achieved negative 90-day returns, with a 100% well-timed rate at this ticker. Fundamentals show a severely strained business model: annual revenue growth of -90.0%, latest-quarter revenue of only $889,000.00, and full-year net income of $-106,441,000.00. The CEO's substantial reduction in holdings amid deep operating losses and a dramatic revenue contraction represents a material shift in his equity exposure to the company.

CFO Prasad Raju sells 29,700 shares at $60.16 avg (81.4% of holdings); company in revenue decline with -$106.4M net loss

Prasad Raju, CFO of CRISPR Therapeutics, executed 3 separate sales totaling 29,700 shares for $1,786,635.87, reducing his holdings from 36,467 shares to 6,767 shares (an 81.4% reduction). The sales occurred at a blended average price of $60.16, which is 6.7% above the current price of $56.40 and near the 52-week high range. The timing of this substantial liquidation warrants attention given CRISPR's underlying business trajectory: the company reported revenue of $889,000.00 in the latest quarter and an annual revenue decline of -90.0% year-over-year, paired with a full-year net loss of -$106,441,000.00. While the sale price itself was not depressed relative to recent trading, the magnitude of the reduction and the company's severe revenue contraction suggest a material shift in the CFO's exposure to the stock. This is the CFO's second concentrated sell event at this ticker within two weeks, following three sales on 2025-12-22, indicating sustained reduction of personal position rather than a one-time adjustment.

CRSP CFO Prasad Raju sold 10,000 shares for $559,548.74 (blended avg $55.95), reducing holdings by 59.6%

Prasad Raju, CFO of CRISPR Therapeutics, executed 3 separate sales on 2025-12-22 totaling 10,000 shares for $559,548.74, reducing his position from 16,767 to 6,767 shares. The sale occurred near the current price level ($56.46), and notably at a time when the stock is -26.5% from its 52-week high of $76.78. The company is operating in a context of significant operational challenges: Revenue contracted 90.0% year-over-year to $889,000.00 in the latest quarter, and the company generated a $-106,441,000.00 net loss, extending unprofitability through the most recent full fiscal year. A CFO disposing of nearly 60% of his holdings in a context of severe revenue contraction and sustained losses warrants investor attention to the underlying financial trajectory and management's perspective on near-term prospects.

CRSP CEO Kulkarni sells 50,895 shares for $3.5M; 4 of 4 prior CRSP sells were well-timed; co. revenue off -90.0% YoY, $892K last qtr, unprofitable.

Samarth Kulkarni, CEO of CRSP, sold 50,895 shares at $67.91 on 2025-10-17, reducing his holdings by 16.7% to 254.2K shares. His prior trade history at CRSP shows a strong execution pattern: all 4 of 4 prior sells were well-timed at the 90-day mark, with the most recent (2025-02-19) followed by a 90-day return of -25.7%, indicating the stock declined after his sales. His cross-ticker track record also shows 100.00% well-timed rate across 20 prior sells, though with an average 90-day return of -19.3%. Against this context of demonstrated timing accuracy, the current sale occurs as CRSP faces severe operational headwinds: revenue contracted 90.0% year-over-year to just $892K in the latest quarter, net income was negative $208.5M, and the company remains unprofitable over its most recent full fiscal year. While CRSP trades near its 52-week high (only -3.7% from the peak of $76.78), the fundamental deterioration combined with his consistent pattern of selling before declines warrants investor attention to the underlying business trajectory.

CRSP CEO sells 13,081 shares at $58.15; stock now $54.16 (-20.5% from 52-week high). All 5 prior CRSP sales well-timed.

Samarth Kulkarni, CRSP's CEO, sold 13,081 shares (13.1K shares) on 2025-08-18 at $58.15, reducing his stake by 5.9% to 207,004 shares (207.0K shares). The stock has since declined to $54.16 and is -20.5% from its 52-week high of $68.14, with a 30-day decline of -16.8%. Critically, all 5 of Kulkarni's prior open-market sales at CRSP were well-timed—each showing negative 90-day returns after execution—and his cross-ticker track record demonstrates a 100.00% well-timed sell rate across 20 prior sales with an average 90-day return of -18.9%. Against this backdrop of consistent prescience, the company's fundamentals are deeply troubled: annual revenue contracted -90.0% to $892,000.00 (latest quarter), net income is $-208,549,000.00 (the company is unprofitable), and market cap stands at $4,925,874,909.68. The insider's sale timing and the company's operational deterioration align as mutually reinforcing signals warrant close investor scrutiny of CRSP's near-term trajectory.

CRSP director Douglas A. Treco purchases 20,000 shares for $1.1M, 10x his prior 2,000-share position

Director Treco Douglas A purchased 20,000 shares at $57.03 on 2025-08-06, expanding his holdings from 2,000 to 22,000 shares—a 1000.0% increase in position size. This is a material acquisition by a board-level insider following substantial recent price momentum: the stock is at $55.00 today, down 19.3% from its 52-week high of $68.14 but up 54.4% over the past 90 days. The purchase occurred in the context of significant fundamental headwinds: CRISPR Therapeutics reported -90.0% annual revenue growth, negative full-year net income of $-208,549,000.00, and quarterly revenue of only $892,000.00, indicating the company is deeply unprofitable and contracting. A director's acquisition of this magnitude warrants investor scrutiny regarding his conviction in the near-term outlook, given the company's deteriorating financial trajectory and whether the 90-day rally presents information asymmetry into the market.

Director George Simeon bought 989,812 shares of CRSP for $51.5M at $52.03 on 2025-07-16 (3 separate transactions)

George Simeon, a Director, executed three separate open-market purchases totaling 989,812 shares for $51,499,918.36, increasing his holdings by 133.7% from 740,367 to 1,730,179 shares. The cumulative investment of $51.5M at a blended average of $52.03 represents a substantial capital commitment, and the stock currently trades at $55.09, 12.2% below its 52-week high and up 27.6% over the past 30 days and 45.9% over the past 90 days. However, Simeon's historical insider trade performance across all tickers is markedly poor: his prior two open-market purchases averaged 90-day returns of -38.7%, with a 0.00% win rate, suggesting his buying has not proven predictive of forward gains. Paired with the company's severe fundamental deterioration—revenue collapsed 90.0% year-over-year to only $865.0K in the latest quarter, net income declined to -$136.0M, and the company remains unprofitable—the large share purchase warrants scrutiny as to whether it reflects strategic conviction or other considerations such as retention, governance, or capital allocation constraints.